Shots:
- Camurus has reported topline P-IIb (POSITANO) trial data assessing 2 dosing regimens of CAM2029 (octreotide SC depot) vs PBO in 71 pts with symptomatic polycystic liver disease (PLD), with pts continuing treatment in a 2.5yr. OLE study
- Trial met its 1EP with a 4.3% relative reduction in height-adjusted liver volume at Wk. 53 for combined CAM2029 groups & an 8.7% reduction in total liver cyst volume; improvements across disease symptoms as well as pts & clinical reported outcomes were also observed. Data to be presented in future meeting
- CAM2029 is also being assessed in an ongoing P-III (SORENTO) trial for GEP-NET, plus a follow-up P-III study for symptomatic PLD is planned for discussion with regulatory authorities
Ref: Prnewswire | Image: Camurus| Press Release
Related News:- Eli Lilly Licenses Camurus’ FluidCrystal Technology to Advance Long-Acting Incretin Products
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
